No Data
No Data
Yantai Zhenghai Bio-Tech (300653.SZ): During the use of active biological bone, doctors decide on the selection of internal fixation devices based on clinical needs. Currently, no related supporting medical devices are provided.
Zhenghai Bio-tech (300653.SZ) stated on the investor interaction platform that the company's active biological bone product is mainly used to fill bone defects caused by trauma or surgery that do not affect the stability of bone structure. During the use of active biological bone, doctors determine the choice of internal fixation devices according to clinical needs, and the company currently does not provide relevant supporting medical devices. Umbilical cord mesenchymal stem cells are currently in the product process validation stage. The company will continue to cultivate in the field of regenerative medicine, actively researching and developing products and technologies including signal molecules, seed cells, additive manufacturing, genetic engineering, and synthetic biology to create medical devices and treatments.
Yantai Zhenghai Bio-Tech (300653.SZ) equity distribution in 2023: 8.01804 yuan per 10 shares.
Zhenghai Bio-Tech (300653.SZ) announced its annual equity distribution plan for 2023: based on the company's existing total share capital after deducting the repurchased shares, it will distribute RMB 8.01804 in cash per 10 shares to all shareholders. The equity distribution share registration date is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Yantai Zhenghai Bio-tech (300653.SZ) has repurchased 0.1679% of its shares, at a cumulative cost of 7.1857 million yuan.
On June 5th, Gelunhui reported that Yantai Zhenghai Bio-Tech (300653.SZ) announced that as of May 31, 2024, the company repurchased 302,300 shares of the company's stock through a share repurchase special securities account through centralized bidding trading, accounting for 0.1679% of the company's total share capital, with a highest transaction price of 24.83 yuan/share, a lowest transaction price of 22.90 yuan/share, and a total amount paid of 7,185,656.74 yuan (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.
Express News | Zhenghai Biotech: Oral Repair Mask Receives Continued Registration
Zhenghai Biology (300653.SZ): The company's active biological bone products were officially marketed in early 2024
Gelonghui, May 15, 丨 Zhenghai Biotech (300653.SZ) was surveyed by specific subjects and said that the company's active biological bone products were officially marketed in early 2024. In the first quarter, it mainly completed online connections in more than 2/3 provinces across the country and admissions work in some hospitals. In the second quarter, it will continue to steadily expand the scope of admission, and sales of related products will gradually increase.
Express News | Zhenghai Biology: The production and preparation process of rhBMP-2, an active factor specifically bound in active biological bone in the marketed product is a synthetic biological technology
No Data